Thrombolytic Therapy
Streptokinase
Tissue Plasminogen Activator
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
Myocardial Infarction
Plasminogen Activators
Anistreplase
An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Urokinase-Type Plasminogen Activator
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Brain Ischemia
Treatment Outcome
Heparin
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Cerebral Hemorrhage
Myocardial Reperfusion
Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY.
Embolectomy
Coronary Care Units
Heart Rupture, Post-Infarction
Intracranial Thrombosis
Electrocardiography
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
Intracranial Hemorrhages
Angioplasty, Balloon, Coronary
Fibrinolysin
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
Carotid Artery Thrombosis
Infusions, Intravenous
Prospective Studies
Coronary Thrombosis
Coronary Angiography
Emergency Medical Services
Intracranial Embolism and Thrombosis
Emergencies
Infusions, Intra-Arterial
Tomography, X-Ray Computed
Intracranial Embolism
Cerebral Infarction
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
Hirudin Therapy
Emergency Treatment
Creatine Kinase
A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins.
Emergency Medical Technicians
Radionuclide Ventriculography
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Hospital Mortality
Thrombectomy
Reperfusion
Restoration of blood supply to tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. It is primarily a procedure for treating infarction or other ischemia, by enabling viable ischemic tissue to recover, thus limiting further necrosis. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing REPERFUSION INJURY.
Fibrinopeptide A
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
Cerebral Angiography
Follow-Up Studies
Fibrinogen
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Fibrin
Patient Selection
Newfoundland and Labrador
Heart Rupture
Randomized Controlled Trials as Topic
Catheterization, Peripheral
Streptodornase and Streptokinase
A mixture of the enzymes (streptokinase and streptodornase) produced by hemolytic streptococci. It is used topically on surface lesions and by instillation in closed body cavities to remove clotted blood or fibrinous or purulent accumulations. It is also used as a skin test antigen in evaluating generalized cell-mediated immunodeficiency. (Dorland, 27th ed) EC 3.-.
Survival Analysis
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Aspirin
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Ecchymosis
Predictive Value of Tests
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
Risk Factors
Cerebrovascular Disorders
Drug Therapy, Combination
Blood Coagulation
Prognosis
Arterial Occlusive Diseases
Fibrin Fibrinogen Degradation Products
Hospitals, Community
Cardiac Catheterization
Ventricular Septal Rupture
Plasminogen
Infarction, Anterior Cerebral Artery
NECROSIS occurring in the ANTERIOR CEREBRAL ARTERY system, including branches such as Heubner's artery. These arteries supply blood to the medial and superior parts of the CEREBRAL HEMISPHERE, Infarction in the anterior cerebral artery usually results in sensory and motor impairment in the lower body.
Registries
Survival Rate
Multivariate Analysis
Iliac Vein
Hemostasis
Vena Cava Filters
Hirudins
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
Community Medicine
Platelet Aggregation Inhibitors
Embolism
Ventricular Dysfunction, Right
A condition in which the RIGHT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE or MYOCARDIAL INFARCTION, and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the right ventricular wall.
Ventricular Function, Left
Heart Diseases
Stroke Volume
Thromboembolism
Heart Block
Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.
Severity of Illness Index
Emergency Service, Hospital
Antifibrinolytic Agents
Catheterization
Magnetic Resonance Imaging
Angioplasty, Balloon
Incidence
Logistic Models
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Heart Valve Prosthesis
Double-Blind Method
Intra-Aortic Balloon Pumping
Counterpulsation in which a pumping unit synchronized with the patient's electrocardiogram rapidly fills a balloon in the aorta with helium or carbon dioxide in early diastole and evacuates the balloon at the onset of systole. As the balloon inflates, it raises aortic diastolic pressure, and as it deflates, it lowers aortic systolic pressure. The result is a decrease in left ventricular work and increased myocardial and peripheral perfusion.
Clinical Trials as Topic
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Age Factors
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Treatment Failure
Magnetic Resonance Angiography
Ultrasonic Therapy
Confounding Factors (Epidemiology)
Factors that can cause or prevent the outcome of interest, are not intermediate variables, and are not associated with the factor(s) under investigation. They give rise to situations in which the effects of two processes are not separated, or the contribution of causal factors cannot be separated, or the measure of the effect of exposure or risk is distorted because of its association with other factors influencing the outcome of the study.
Tomography, Emission-Computed, Single-Photon
A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.
Drug Administration Schedule
Ultrasonography, Doppler, Transcranial
A non-invasive technique using ultrasound for the measurement of cerebrovascular hemodynamics, particularly cerebral blood flow velocity and cerebral collateral flow. With a high-intensity, low-frequency pulse probe, the intracranial arteries may be studied transtemporally, transorbitally, or from below the foramen magnum.
Middle Cerebral Artery
Echocardiography
Coronary Disease
Brain
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
Combined Modality Therapy
Coronary Artery Bypass
Thallium Radioisotopes
Disease Models, Animal
Immunoglobulin Fab Fragments
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Platelet Aggregation
Ischemia
Drug Utilization
Dogs
Arrhythmias, Cardiac
Sensitivity and Specificity
Regression Analysis
Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable.
Constriction, Pathologic
Physician's Practice Patterns
Diffusion Magnetic Resonance Imaging
A diagnostic technique that incorporates the measurement of molecular diffusion (such as water or metabolites) for tissue assessment by MRI. The degree of molecular movement can be measured by changes of apparent diffusion coefficient (ADC) with time, as reflected by tissue microstructure. Diffusion MRI has been used to study BRAIN ISCHEMIA and tumor response to treatment.
Stents
Risk Assessment
Carotid Artery, Internal
Neurologic Examination
Optimal thrombolytic strategies for acute myocardial infarction--bolus administration. (1/2653)
Optimal strategies for thrombolysis in myocardial infarction (TIMI) are still being sought because the TIMI 3 flow rates achievable using standard regimens average approximately 60%. Double bolus administration of recombinant tissue plasminogen activator (tPA) is a novel approach with potential for earlier patency combined with ease of administration. We reviewed total patency rates, TIMI 3 patency rates, mortality, stroke and intracranial haemorrhage rates in the major trials of accelerated infusion tPA/bolus tPA/reteplase in acute myocardial infarction. A direct comparison was performed with results of two recent trials of double bolus (two 50 mg boli, 30 min apart) vs. accelerated infusion tPA: the Double Bolus Lytic Efficacy Trial (DBLE), an angiographic study, and the COBALT Trial, a mortality study. The DBLE trial showed equivalent patency rates for accelerated infusion and double bolus administration of tPA. Reviewing other angiographic trials, total patency and TIMI 3 patency rates achievable with double bolus tPA were comparable to those with accelerated infusion tPA or bolus reteplase administration. The COBALT study demonstrated a 30-day mortality of 7.53% in patients treated with accelerated infusion tPA compared with 7.98% for double bolus tPA treated patients. The small excess in mortality with double bolus treatment was confined to the elderly; in those < or = 75 years, mortality rates were 5.6% and 5.7%, for double bolus and accelerated infusion, respectively, and rates for death or non-fatal stroke were 6.35% and 6.3%, respectively. Comparison with other trials demonstrated mortality, stroke and intracranial haemorrhage rates with double bolus treatment similar to those associated with either accelerated infusion tPA or bolus reteplase treatment. Double bolus administration of tPA to patients with acute myocardial infarction is associated with total patency, TIMI 3 patency, mortality, stroke and intracranial haemorrhage rates similar to those associated with either accelerated infusion of tPA or bolus reteplase. (+info)Age-related outcome for peripheral thrombolysis. (2/2653)
OBJECTIVES: To investigate the age-related outcome of peripheral thrombolysis and determine for which patient group this treatment is worthwhile. DESIGN AND METHODS: A combined retrospective and prospective analysis of consecutive patients undergoing thrombolysis for acute lower-limb ischaemia was made with respect to age-related outcome and other risk factors. RESULTS: One hundred and two patients underwent thrombolysis for acute limb ischaemia. In the under 60 age group there was a 40% amputation rate. Seventy-three per cent of this group smoked. In the over 80 age group, the amputation rate was 15% and only 8% were smokers. CONCLUSION: Advancing age is not an adverse risk factor for thrombolysis which appears to be safe and effective in this patient group. There is a high incidence of smoking in the younger age group (< 60 years), in whom failed thrombolysis frequently leads to amputation. (+info)Delayed increase in infarct volume after cerebral ischemia: correlations with thrombolytic treatment and clinical outcome. (3/2653)
BACKGROUND AND PURPOSE: Growing experimental evidence indicates that the development of cerebral ischemic damage is slower than previously believed. The aims of this work were (1) to study the evolution of CT hypoattenuation between 24 to 36 hours and 7 days in ischemic stroke patients; (2) to evaluate whether thrombolytic treatment given within 6 hours of stroke affects delayed infarction evolution; and (3) to investigate possible correlations between lesion volume changes over time and clinical outcome. METHODS: Of 620 patients included in the European Cooperative Acute Stroke Study 1 (ECASS1), we selected 450 patients whose control CT scans at day 1 (CT1) and day 7 (CT7) were available. They had been randomly divided into 2 groups: 206 patients had been treated with rtPA and 244 with placebo. CT1 and CT7 were classified according to the location of the infarct. The volume of CT hypoattenuation was measured using the formula AxBxC/2 for irregular volumes. The 95% confidence interval of inter- and intrarater variability was used to determine whether significant changes in lesion volume had occurred between CT1 and CT7. Clinical severity was evaluated by means of the Scandinavian Stroke Scale (SSS) at entry (SSS0) and at day 30 (SSS30). RESULTS: Mean lesion volumes were significantly (P<0.0001) higher at day 7 than at day 1 in all the subgroups of patients and particularly in patients with a subcortical lesion. Of the 450 patients studied, 287 (64%) did not show any significant change in lesion volume between CT1 and CT7, 143 (32%) showed a significant increase and the remaining 20 (4%) a significant decrease. No significant correlation was observed between treatment and lesion evolution between CT1 and CT7. Both clinical scores (SSS0 and SSS30) and degree of neurological recovery were significantly (P<0.05) lower in the subgroup of patients with a significant lesion volume increase than in the other 2 groups. CONCLUSIONS: In approximately two thirds of patients, infarct size is established 24 to 36 hours after stroke onset, whereas in the remaining one third, changes in lesion volume may occur later than the first 24 to 36 hours. Many factors may be responsible for delayed infarct enlargement and for a lower degree of clinical recovery, both of which may occur despite early recombinant tissue plasminogen activator treatment. (+info)Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. (4/2653)
BACKGROUND AND PURPOSE: We tested the hypothesis that treatment of embolic stroke with recombinant human tissue plasminogen activator (rhtPA) alters cerebral expression of adhesion molecules. METHODS: Male Wistar rats were subjected to middle cerebral artery occlusion by a single fibrin-rich clot. P-selectin, E-selectin, and intercellular adhesion molecule-1 (ICAM-1) immunoreactivity was measured at 6 or 24 hours after embolic stroke in control rats and in rats treated with rhtPA at 1 or 4 hours after stroke. To examine the therapeutic efficacy of combined rhtPA and anti-ICAM-1 antibody treatment at 4 hours after embolization, ischemic lesion volumes were measured in rats treated with rhtPA alone, rats treated with rhtPA and anti-ICAM-1 antibody, and nontreated rats. RESULTS: Administration of rhtPA at 1 hour after embolization resulted in a significant reduction of adhesion molecule vascular immunoreactivity after embolization in the ipsilateral hemisphere compared with corresponding control rats. However, when rhtPA was administered to rats at 4 hours after embolization, significant increases of adhesion molecule immunoreactivity in the ipsilateral hemisphere were detected. A significant increase of ICAM-1 immunoreactivity was also detected in the contralateral hemisphere at 24 hours after ischemia. A significant reduction in lesion volume was found in rats treated with the combination of rhtPA and anti-ICAM-1 antibody compared with rats treated only with rhtPA. CONCLUSIONS: The present study suggests that the time of initiation of thrombolytic therapy alters vascular immunoreactivity of inflammatory adhesion molecules in the ischemic brain and that therapeutic benefit can be obtained by combining rhtPA and anti-ICAM-1 antibody treatment 4 hours after stroke. (+info)Carotid endarterectomy and intracranial thrombolysis: simultaneous and staged procedures in ischemic stroke. (5/2653)
PURPOSE: The feasibility and safety of combining carotid surgery and thrombolysis for occlusions of the internal carotid artery (ICA) and the middle cerebral artery (MCA), either as a simultaneous or as a staged procedure in acute ischemic strokes, was studied. METHODS: A nonrandomized clinical pilot study, which included patients who had severe hemispheric carotid-related ischemic strokes and acute occlusions of the MCA, was performed between January 1994 and January 1998. Exclusion criteria were cerebral coma and major infarction established by means of cerebral computed tomography scan. Clinical outcome was assessed with the modified Rankin scale. RESULTS: Carotid reconstruction and thrombolysis was performed in 14 of 845 patients (1.7%). The ICA was occluded in 11 patients; occlusions of the MCA (mainstem/major branches/distal branch) or the anterior cerebral artery (ACA) were found in 14 patients. In three of the 14 patients, thrombolysis was performed first, followed by carotid enarterectomy (CEA) after clinical improvement (6 to 21 days). In 11 of 14 patients, 0.15 to 1 mIU urokinase was administered intraoperatively, ie, emergency CEA for acute ischemic stroke (n = 5) or surgical reexploration after elective CEA complicated by perioperative intracerebral embolism (n = 6). Thirteen of 14 intracranial embolic occlusions and 10 of 11 ICA occlusions were recanalized successfully (confirmed with angiography or transcranial Doppler studies). Four patients recovered completely (Rankin 0), six patients sustained a minor stroke (Rankin 2/3), two patients had a major stroke (Rankin 4/5), and two patients died. In one patient, hemorrhagic transformation of an ischemic infarction was detectable postoperatively. CONCLUSION: Combining carotid surgery with thrombolysis (simultaneous or staged procedure) offers a new therapeutic approach in the emergency management of an acute carotid-related stroke. Its efficacy should be evaluated in interdisciplinary studies. (+info)The surgical management of acute limb ischaemia due to native vessel occlusion. (6/2653)
OBJECTIVES: Data from the STILE study have indicated that for patients with subacute limb ischaemia due to native vessel occlusion, surgery is both more effective, and durable than thrombolysis. The purpose of this study was to evaluate the outcome of an aggressive surgical approach in patients presenting with acute limb-threatening ischaemia. DESIGN: Details of patients presenting with salvageable acute limb ischaemia due to native artery occlusion over a 6-year period in a University hospital vascular unit setting were obtained from the vascular audit and the outcome of the surgical management of these patients was analysed. RESULTS: One hundred and seventy-four consecutive patients underwent surgery for acute native vessel limb ischaemia (76% lower, 24% upper limb). Fogarty thrombectomy or embolectomy was initially performed in 153 (89%) patients. Of these, 37 (24%) immediately underwent a further procedure: 28 (18%) had on-table thrombolysis and 14 (9%) underwent vascular reconstruction. Twenty-six patients (15%) underwent further limb salvage surgery within 30 days. Life table analysis demonstrated a limb salvage rate of 88% and 76% at 30 days and 2 years, respectively. Patient survival was 75% and 48% at the same time intervals. CONCLUSIONS: These results demonstrate that a role for aggressive surgical intervention still exists, resulting in high limb salvage rates. (+info)Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. (7/2653)
BACKGROUND: We investigated whether administration of a soluble recombinant P-selectin glycoprotein ligand-1 chimera (rPSGL-Ig) in conjunction with thrombolytic therapy would enhance thrombolysis by preventing ongoing interactions of leukocytes with platelets and the injured arterial wall. METHODS AND RESULTS: An occlusive thrombus was formed in an internal iliac artery of Yorkshire pigs by placement of a copper coil in the artery under fluoroscopic guidance. Pigs then received heparin and, 15 minutes later, either vehicle or rPSGL-Ig followed by infusion with 25 mg tissue plasminogen activator according to the 90-minute regimen. Blood flow through the artery was monitored by angiography and scored on a scale of 0 to 3. Lysis of the thrombus was accelerated by 70% in pigs treated with rPSGL-Ig 250 microg/kg compared with control (13.3+/-5.0 versus 44. 4+/-13.3 minutes; n=9 each). Eight of 9 control pigs reoccluded in 13.8+/-16.9 minutes after the end of tissue plasminogen activator infusion, whereas no reocclusion was observed in 8 of 9 pigs in the rPSGL-Ig group. When the dose of rPSGL-Ig was increased to 500 microg/kg, time to lysis was shortened by 61% from control (18.0+/-8. 4 versus 46.0+/-8.9 minutes). Reocclusion occurred in 6.0+/-15.2 minutes in control but not in any rPSGL-Ig-treated pig (n=5 each). In addition, near-normal flow (score 2 or 3) after thrombolysis was achieved 59% and 58% faster in the 2 rPSGL-Ig groups than in their respective controls. CONCLUSIONS: Inhibition of leukocyte accumulation at the site of thrombosis with rPSGL-Ig may represent a safe therapeutic intervention that could be important in accelerating thrombolysis, achieving optimal reperfusion, and reducing incidence of acute reocclusion. (+info)Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. (8/2653)
OBJECTIVES: This study compares the efficacy of primary angioplasty and systemic thrombolysis with t-PA in reducing the in-hospital mortality of patients with anterior AMI. BACKGROUND: Controversy still exists about the relative benefit of primary angioplasty over thrombolysis as treatment for AMI. METHODS: Two-hundred and twenty patients with anterior AMI were randomly assigned in our institution to primary angioplasty (109 patients) or systemic thrombolysis with accelerated t-PA (111 patients) within the first five hours from the onset of symptoms. RESULTS: Baseline characteristics were similar in both groups. Primary angioplasty was independently associated with a lower in-hospital mortality (2.8% vs. 10.8%, p = 0.02, adjusted odds ratio 0.23, 95% confidence interval 0.06 to 0.85). During hospitalization, patients treated by angioplasty had a lower frequency of postinfarction angina or positive stress test (11.9% vs. 25.2%, p = 0.01) and less frequently underwent percutaneous or surgical revascularization after the initial treatment (22.0% vs. 47.7%, p < 0.001) than did patients treated by t-PA. At six month follow-up, patients treated by angioplasty had a lower cumulative rate of death (4.6% vs. 11.7%, p = 0.05) and revascularization (31.2% vs. 55.9%, p < 0.001) than those treated by t-PA. CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. (+info)
Increase in national intravenous thrombolysis rates for ischaemic stroke between 2005 and 2012: is bigger better? | BMC...
Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct...
The relationship of intracoronary stent placement following thrombolytic therapy to tissue level perfusion<...
Computed tomography scan following thrombolytic therapy | Open-i
Retrospective observational case-control study comparing prehospital thrombolytic therapy for ST-elevation myocardial...
10 Best Clinics for Intravenous Thrombolytic Therapy in Wiesbaden [2021 Prices]
10 Best Clinics for Intravenous Thrombolytic Therapy in France [2020 Prices]
CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction<...
Use of CT angiography in patient selection for thrombolytic therapy<...
Best Thrombolytic Therapy Doctor in Mumbai, Thrombolytic Therapy Doctors | Credihealth
ST segment monitoring for coronary artery reocclusion following thrombolytic therapy and coronary angioplasty: identification...
Intra-Arterial Thrombolysis for Left Middle Cerebral Artery Embolic Stroke During Coronary Angiography | Circulation
A Case of Acute Myocardial Infarction after Thrombolytic Therapy for Mechanical Valve Dysfunction in the Late Postoperative...
Hospitalization Costs for Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis in the United States Are...
Administration of thrombolytic therapy to patients with acute myocardial infarction - Kingston University Research Repository
Efficiency of Intravenous Thrombolytic Therapy in Isolated Middle Cerebral Artery Occlusions: A Computed Tomography Angiography...
Audit of prehospital thrombolysis by general practitioners in peripheral practices in Grampian | Heart
Taipei Medical University Shuang Ho Hospital
Effect of Thrombolytic Therapy on the Evolution of Baroreceptor Sensitivity After Myocardial Infarction | Clinical Science
Relationships between brain perfusion and early recanalization after intravenous thrombolysis for acute stroke with large...
Rescue angioplasty reduced cardiovascular and cerebrovascular outcomes in acute MI after failed thrombolytic therapy | Annals...
Age-Specific Differences in the Use of Thrombolytic Therapy and Hospital Outcomes in Patients with Acute Myocardial Infarction:...
Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction
Avoiding Pseudo-Reversibility of CT-CBV Infarct Core Lesions in Acute Stroke Patients After Thrombolytic Therapy | Stroke
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial...
Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis<...
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis:...
Tips From Other Journals - American Family Physician
Thrombolytic Therapy | Sutter Health
Thrombolytic Therapy | Sutter Health
Mechanical Thrombolysis in Acute Stroke: Mechanical Thrombolytic Treatment Techniques, Stent Retriever Devices, Other...
Western Pacific Region Index Medicus
Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System. - ppt download
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery - Tabular View -...
high-risk PE
Rapid Early Action for Coronary Treatment (REACT) - Full Text View - ClinicalTrials.gov
Clinical Trials Registry | Internet Stroke Center
thrombolytic therapy implications for patient management
Cost-effectiveness of Perfusion Imaging With Computed Tomographyto Identify Patients for Intravenous Thrombolysis: A Hospital...
How early one can shift a patient for rescue PCI after failed thrombolysis ? | Dr.S.Venkatesan MD
Difference between revisions of Thrombolytics for STEMI - WikEM
Thrombolytic Treatment Before Stenting Linked to Increased Mortality | Medpage Today
thrombolysis
Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review | Journal of...
Heart-and-Stroke-Encyclopedia - 2010-06-03 - The Golden Hour and Acute Brain Ischemia: Presenting Features and Lytic Therapy in...
Bruno-Marcel Mackert | Vivantes
Is the time window for primary PCI different from thrombolysis ? | Dr.S.Venkatesan MD
Get PDF - Acute neonatal arterial occlusion: is thrombolysis safe and effective?
Early intravenous thrombolytic therapy for acute myocardial infarction in patients with prior coronary artery bypass grafts<...
Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic...
Thrombolytic treatment of acute ischemic stroke<...
Catheter-Directed Thrombolysis for Pulmonary Embolism | JACC: Cardiovascular Interventions
1995 - Streptokinase led to higher 10-day and 6-month case fatality rates in acute
stroke | 1996 May-Jun : Volume 124...
Percutaneous treatment of failed native dialysis fistulas: use of pulse-spray pharmacomechanical thrombolysis as the primary...
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in...
Questionnaire survey of thrombolytic treatment in accident and emergency departments in the United Kingdom | The BMJ
Thrombolytic therapy for acute ischemic stroke - Eesti Arst - Eesti Arstide Liidu ajakiri
Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism | Circulation
Is prehospital thrombolysis for acute myocardial infarction warranted in the urban setting? The case against | Emergency...
A Case Report of Atrial Myxoma presenting with Cardioembolic Stroke and treated with Intravenous Thrombolytic Therapy | Journal...
Higher Annual Operator Volume Is Associated With Better Reperfusion Rates in Stroke Patients Treated by Mechanical Thrombectomy...
Assessment of neurologists knowledge regarding intravenous fibrinolytic therapy for acute stroke in Shanxi province in China |...
Get PDF - Long term follow up after thrombolytic therapy
Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and...
Timeliness of Intravenous Thrombolysis via Telestroke in Georgia | National Minority Quality Forum a not-for-profit...
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction : a subgroup analysis of the...
Intravenous Thrombolysis for Ischemic Stroke Patients on Dual Antiplatelets<...
Tips From Other Journals - American Family Physician
1993 - Late thrombolysis improved survival only if given within 12 hours of onset
of acute myocardial infarction...
Thrombolytic treatment in stroke mimic, inevitable but fortunately safe: An observational study from Iran
Stenting versus thrombolysis in acute myocardial infarction trial (STAT).
Most recent papers with the keyword Thrombolytic therapy | Read by QxMD
Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the...
T-cell recognition of discrete regions of the thrombolytic drug streptokinase | Clinical Science
STElevation Myocardial Infarction Thrombolytic Therapy - Myocardial Infarction
Pilot and Preliminary Studies of Thrombolytic Therapy for Stroke | Springer for Research & Development
Dr. Smiths ECG Blog: Chest Pain and Cardiogenic Shock with Profound ST Depression & STE in aVR. Activate the Cath Lab?
THROMBOLYTICS TO AID CLOT LYSIS IN INTRACEREBRAL HAEMORRHAGE: IDENTIFYING STRATEGIES TO MAXIMISE BENEFIT | Research Explorer |...
Clinical Trials Registry | Internet Stroke Center
Thrombolysis in cerebral infarction (TICI) scale | Radiology Reference Article | Radiopaedia.org
Successful treatment of an acute sub-massive pulmonary embolism in a renal transplant patient with thrombolytic of low dosage...
24-7 Drugstore: Suplement recover from propecia lowest price guaranteed!
Schlaganfall
Acute Myocardial Infarction (AMI) Sapulpa OK - Acute myocardial infarction, Sapulpa OK AMI, Sapulpa OK MI, Sapulpa OK heart...
Proteases (medical and related uses)
Rivera-Bou WL, Cabanas JG, Villanueva SE (2008-11-20). "Thrombolytic Therapy". Medscape. Wardlaw JM, Murray V, Berge E, del ... Maggot therapy for wound debridement is a traditional therapy which was in recent years approved by the FDA. It has been ... See article Maggot therapy -- Regulation and references cited therein. Reames MK, Christensen C, Luce EA (October 1988). "The ... It is one of the enzymes in Sollpura (Liprotamase), a pancreatic enzyme replacement therapy (PERT). It assists in the break ...
Tissue plasminogen activator
"Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction". Medscape. Tsurupa ... Rivera-Bou WL, Cabanas JG, Villanueva SE (2008-11-20). "Thrombolytic Therapy". Medscape. Wardlaw JM, Murray V, Berge E, del ... "Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy". Archives of Surgery. 142 (6): 546-51, ... with one resulting in desired thrombolytic activity (see figure). For starters, following administration and release, tPA can ...
Plasminogen activator
Rivera-Bou WL (15 December 2016). "Thrombolytic Therapy". MedScape. Retrieved 28 February 2017. Law RH, Caradoc-Davies T, ... resulting in an increased capacity to treat thrombolytic diseases. Urokinase is similarly used in the medical field, ...
Arteriosclerosis
Thrombolytic therapy: This is a treatment used to break up masses of plaque inside the arteries via intravenous clot-dissolving ... MedlinePlus Encyclopedia: Thrombolytic therapy "Atherosclerosis". Merck Manuals. Retrieved 13 February 2015. Mayerl, Christina ... Medical therapy is often prescribed to help prevent arteriosclerosis for underlying conditions, such as medications for the ...
Pulmonary embolism
Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W (July 2014). "Impact of the efficacy of thrombolytic therapy on the mortality ... Zuo, Zhiliang; Yue, Jirong; Dong, Bi Rong; Wu, Taixiang; Liu, Guan J.; Hao, Qiukui (2021-04-15). "Thrombolytic therapy for ... Ucar, Elif Yilmazel (June 2019). "Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism". The Eurasian Journal of ... transgender hormone therapy, menopausal hormone therapy and hormonal contraceptives) Genetic thrombophilia (factor V Leiden, ...
Intra-aortic balloon pump
Thrombolytic therapy of acute myocardial infarction. The following conditions will always exclude patients for treatment: ... The patient, a 48-year-old woman, was in cardiogenic shock and unresponsive to traditional therapy. An IABP was inserted by a ... Aortic dissection Severe aortoiliac occlusive disease and bilateral carotid stenosis The following conditions make IABP therapy ...
Harbans Singh Wasir
Shyam Sunder Kothari; Sudhir Varma; Harbans Singh Wasir (March 1994). "Thrombolytic therapy in infants and children". American ... Shyam Sunder Kothari; Sudhir Varma; Harbans Singh Wasir (March 1994). "Thrombolytic therapy in infants and children". American ...
Thrombolysis
Hemorrhagic stroke is a rare but serious complication of thrombolytic therapy. If a patient has had thrombolysis before, an ... Wechsler LR (2011). "Intravenous thrombolytic therapy for acute ischemic stroke". N Engl J Med. 364 (22): 2138-46. doi:10.1056/ ... Anaphylaxis generally requires immediate cessation of thrombolysis.[citation needed] Thrombolysis therapy uses thrombolytic ... In people who receive thrombolytic therapy delivered through a catheter, there is a risk of hemorrhage as a side effect. ...
Embolectomy
Thrombolytic therapy has become the treatment of choice. Surgical or catheter embolectomy is normally performed in patients ... for patients with persisting shock despite supportive care and who have an absolute contraindication for thrombolytic therapy. ...
Ancrod
... rethrombosis after thrombolytic therapy and rethrombosis after vascular surgery. It is also indicated for the prevention of ... Platelet counts and survival time remain normal during ancrod therapy. Ancrod was originally isolated from the venom of the ... and facilitates physical and ergo therapy. Finally, ancrod decreases the likelihood of local thrombotic events. These ...
John A. Ambrose
"Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. ...
Glenn Laffel
Laffel, Glenn; Braunwald, Eugene (1986). "Management of the Residual Stenosis following Thrombolytic Therapy of Acute ...
Frostbite
"Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy". Archives of Surgery. 142 (6): 546-51. ... Evidence is insufficient to determine whether or not hyperbaric oxygen therapy as an adjunctive treatment can assist in tissue ... Weaver LK, Greenway L, Elliot CG (1988). "Controlled Frostbite Injury to Mice: Outcome of Hyperbaric Oxygen Therapy". J. ... "Delayed treatment of frostbite injury with hyperbaric oxygen therapy: a case report". Aviat Space Environ Med. 73 (4): 392-4. ...
Thrombosis
If diagnosed within 12 hours of the initial episode (attack) then thrombolytic therapy is initiated.[citation needed] An ... September 2004). "Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy ... Treatment varies between therapy and surgical intervention by the use of shunts. Portal vein thrombosis affects the hepatic ... Hence, protective therapies are required to attenuate IRI alongside reperfusion in acute ischemic conditions to improve ...
Reperfusion therapy
Thrombolytic therapy to abort a myocardial infarction is not always effective. The degree of effectiveness of a thrombolytic ... Thrombolytic therapy is indicated for the treatment of STEMI - if it can begin within 12 hours of the onset of symptoms, and ... 2002). "Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to ... The benefit of prompt, primary angioplasty over thrombolytic therapy for acute STEMI is now well established. When performed ...
Antiplatelet drug
Treatment of established arterial thrombosis includes the use of antiplatelet drugs and thrombolytic therapy. Antiplatelet ... Antiplatlet therapy may increase the risk of a bleed during surgery, however, stopping therapy may increase the risk of other ... Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the ... The same review found that continuing or discontinuing therapy also did not have a big difference on the incidence of bleeds ...
Discovery and development of direct thrombin inhibitors
"Heparin and Low-Molecular-Weight Heparin The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest. 126 (3 ... Anticoagulation therapy has a long history. In 1884 John Berry Haycraft described a substance found in the saliva of leeches, ... Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of ... which returned to baseline after cessation of therapy. Development of other oral DTIs, such as Sofigatran from Mitsubishi ...
Heparin
... the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest. 126 (3 Suppl): 188S-203S. doi:10.1378/chest. ... Principles of Antithrombotic Therapy". In Lichtman MA, Beutler E, Kipps TJ, et al. (eds.). Williams Hematology (7th ed.). ISBN ... The hyperkalemia can appear within a few days after the onset of heparin therapy. More rarely, the side-effects alopecia and ... Segura MM, Kamen A, Trudel P, Garnier A (May 2005). "A novel purification strategy for retrovirus gene therapy vectors using ...
Thrombotic storm
Treatment for thrombotic storm may include lifelong anticoagulation therapy and/or thrombolytic therapy, plasmapheresis, and ... Studies have shown that when anticoagulant therapy is withheld, recurrence of thrombosis usually follows. International ...
Désiré Collen
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical ... 2004; 110: 744-9. Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst ... 1985; 312: 932-6. Sheehan FH et al., The effect of intravenous thrombolytic therapy on left ventricular function: a report on ... However, because access to invasive facilities is limited in many countries, thrombolytic therapy is still employed in many ...
Management of acute coronary syndrome
Some Paramedic services are capable of providing thrombolytic therapy in the prehospital setting, allowing reperfusion of the ... and reperfusion therapy is more often reserved for them. Long-term therapy is necessary for prevention of recurrent events and ... Medical therapy for acute coronary syndromes is based on drugs that act against ischemia and resultant angina and limit the ... Patients at low risk can be adequately treated with medical therapy, in many ways similar to the one used for STEMI (but ...
Cerebral infarction
... thrombolytic drugs were introduced in the therapy of cerebral infarction. The use of intravenous rtPA therapy can be advocated ... cognitive therapy, occupational therapy, speech therapy and exercise. Permissive hypertension - allowing for higher than normal ... If cerebral infarction is caused by a thrombus occluding blood flow to an artery supplying the brain, definitive therapy is ... the best course of action is to make every effort to restore impairments through physical therapy, ...
L. Royal Christensen
Described as thrombolytic therapy, this treatment was named as one of the top 10 discoveries in cardiology in the 20th century ...
Gundu Hirisave Rama Rao
2007, ISBN 81-8061-936-2 Rao, GHR: (Editor): Clinical Handbook of Management of Antithrombotic & Thrombolytic Therapy. ...
Fondaparinux
February 2008). "The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup ...
Peter H. Lin
... in endovascular intervention in part contributed to the clinical approval of treatment indication using thrombolytic therapy in ... His clinical interests primarily involve minimally invasive endovascular therapy of deep vein thrombosis, peripheral arterial ... experimental models of endovascular therapy, and thrombolysis in arterial and venous thrombosis research. Lin's research ... Perspectives in Vascular Surgery and Endovascular Therapy. 22 (3): 171-182. doi:10.1177/1531003510379880. PMID 21098498. Lin, P ...
Sgarbossa's criteria
A large clinical trial of thrombolytic therapy for MI (GUSTO-1) evaluated the electrocardiographic diagnosis of evolving MI in ... Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials". American Heart Journal ...
Anterior cerebral artery syndrome
... as contraindications to thrombolytic therapy should undergo rapid assessment. Cardiac sources of embolism can be evaluated as ... Dual antiplatelet therapy (aspirin and clopidogrel) are recommended to start within 24 hours for 21 days in patients with minor ... Antiplatelet therapy or anticoagulants are not recommended within 24h after alteplase administration. Aspirin is not a ... The CHANCE trial showed that the primary outcome of recurrent stroke at 90 days favored dual antiplatelet therapy over Aspirin ...
Aortic dissection
If the myocardial infarction is treated with thrombolytic therapy, the mortality increases to over 70%, mostly due to bleeding ... These individuals have been self-selected as survivors of the acute episode and can be treated with medical therapy as long as ... Complicated Stanford type B aortic dissections require surgical intervention after initiation of medical therapy.[citation ...
Percutaneous coronary intervention
... but this is less than the risk of a stroke following thrombolytic drug therapy. As with any procedure involving the heart, ... 85% of patients in the medical therapy arm elected to have PCI at the end of the trial. The 2019 ISCHEMIA trial has confirmed ... The length of time a patient needs to be on dual antiplatelet therapy is individualized based risks of ischemic events and ... The study compared stenting as used in PCI to medical therapy alone in symptomatic stable coronary artery disease (CAD). This ...
Balaji Sadasivan
Morgan, Jay K.; Sadasivan, Balaji; Ausman, James I.; Mehta, Bharat (January 1990), "Thrombolytic therapy and posterior ...
List of Ig Nobel Prize winners
Schröder, Arjan E.; Vulink, Nienke C.; van Loon, Arnoud J.; Denys, Damiaan A. (1 August 2017). "Cognitive behavioral therapy is ... Investigators, T. G. (1993). "An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial ... Behaviour Research and Therapy. 45 (5): 977-987. doi:10.1016/j.brat.2006.07.009. PMID 16989773. Stephens, R.; Atkins, J.; ... for his determined use of electroshock therapy. At his own insistence, automobile spark plug wires were attached to his lip, ...
Management of atrial fibrillation
Conference on Antithrombotic and Thrombolytic Therapy recommends initiating warfarin without heparin bridging. While there is a ... Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I (2007). "Meta-analysis of magnesium therapy for the acute ... A trial comparing closure against warfarin therapy found closure to be non-inferior when measured against a composite end point ... 2008). "Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice ...
Cholesterol embolism
... is treated by removing the cause and giving supportive therapy; statin drugs have been found to improve ... cholesterol embolism may develop after the commencement of anticoagulants or thrombolytic medication that decrease blood ...
TIMI
... 2A compared the results of 3 strategies of coronary angiography and angioplasty following intravenous thrombolytic therapy ... standard-dose prophylactic anticoagulation and antiplatelet therapy vs. no antiplatelet therapy on the risk of venous or ... ENTIRE-TIMI 23 assessed the safety and efficacy of enoxaparin as an adjunct to thrombolysis with or without GP IIb/IIIa therapy ... evaluated the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy ...
Vertebral artery dissection
The thrombolytic drug is administered either intravenously or during cerebral angiography through a catheter directly into the ... Anticoagulation is regarded as more powerful than antiplatelet therapy, but anticoagulants may increase the size of the ... "endovascular therapy" (inside the blood vessel). This may be performed to allow the blood to flow through a severely narrowed ... "Cervical Arterial Dissections and Association With Cervical Manipulative Therapy: A Statement for Healthcare Professionals From ...
Dextran
In this family, dextran-40 (MW: 40,000 Da), has been the most popular member for anticoagulation therapy. Close to 70% of ... so possesses thrombolytic features. Outside of these features, larger dextrans, which do not pass out of the vessels, are ... Brooks and others recommend the avoidance of dextran therapy in patients with chronic kidney disease. Efforts have been made to ...
Temple University School of Medicine
Sol Sherry MD, revolutionized the treatment of acute MI through his pioneering work in thrombolytic therapy and trained many of ... Joseph Wolpe M.D., psychiatrist and father of behavioral modification therapy Bernard T. Mittemeyer M.D., former Surgeon ...
Neonatal stroke
Combined therapies of hypothermia and pharmacological agents or growth factors to improve neurological outcomes are most likely ... but the bleeding risks associated with thrombolytic agents are still unclear. Heparin, an anticoagulant, treatments have been ... but it is not yet known if this therapy is likely to be successful. Aden, U. (2009). Neonatal Stroke Is Not a Harmless ... it is not yet known if this therapy is likely to be successful. Neonatal strokes may lead to cerebral palsy, learning ...
Urine
... contains proteins and other substances that are useful for medical therapy and are ingredients in many prescription drugs ... which is used clinically as a thrombolytic agent.[citation needed] Urine contains large quantities of nitrogen (mostly as urea ... Drinking urine (urophagia) Ureotelic Urine therapy Urolagnia, an attraction to urine Cite error: The named reference diet-adj ... health implication of urine therapy Many physicians in ancient history resorted to the inspection and examination of the urine ...
Acute coronary syndrome
The time frame for door-to-needle thrombolytic administration according to American College of Cardiology (ACC) guidelines ... Cardiovascular Diagnosis and Therapy. 9 (3): 281-298. doi:10.21037/cdt.2019.04.03. PMC 6603494. PMID 31275818. Tamis-Holland, ...
Andrew Nicolaides
The multidisciplinary approach combining angiography, high-resolution ultrasound, thrombolytic therapy, plaque pathology, ...
Electrocardiography
... and has resulted in improper diagnosis and treatment including unnecessary use of thrombolytic therapy. Numerous diagnoses and ...
Richard Whitlock
In 2012, Whitlock authored the 2012 American College of Chest Physicians guideline on antithrombotic and thrombolytic therapy ...
St. Francis Hospital (Columbus, Georgia)
Breast cancer is typically treated by using a combination of local therapy as well as systemic therapy. The goal of local ... In a typical cardiac emergency, thrombolytic drugs can be utilized sometimes in order to dissolve blood clots and as a useful ... Systemic therapy involves destroying tumor cells that may have diluted into the circulation while at the same time it minimizes ... Francis Orthopaedic Institute, the physical therapy gymnasium of the St. Francis Rehabilitation Center, and the operating rooms ...
Streptokinase
... (SK) is a thrombolytic medication and enzyme. As a medication it is used to break down clots in some cases of ... unresponsive to emergency therapy) For streptokinase, prior treatment within the previous 6 months History of chronic, severe, ... internal bleeding Noncompressible vascular punctures Active peptic ulcer Oral anticoagulant therapy Streptokinase belongs to a ...
Cerebroprotectant
Choose the best candidates from pre-clinical (animal) studies A 2006 analysis of studies for 1,026 therapies in stroke and ... Clinical trial number NCT02452502 for "The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in ... Pasban E, Panahpour H, Vahdati A (June 2017). "Early oxygen therapy does not protect the brain from vasogenic edema following ... Nighoghossian N, Ovize M, Mewton N, Ong E, Cho TH (2016). "Cyclosporine A, a Potential Therapy of Ischemic Reperfusion Injury. ...
Paradoxical embolism
... anti-platelet therapy like aspirin and clopidogrel, and thrombolytic therapy like alteplase and streptokinase. If an embolus is ... Amin; Kresowik; Nicholson (2014). Current Therapy in Vascular and Endovascular Surgery, Fifth Edition. Elsevier. pp. 629-631. ...
Ischemic Stroke Complicating Thrombolytic Therapy for STEMI
These two cases highlight the rare complication of ischemic stroke following fibrinolytic therapy for STEMI. What mechanism ... Ischemic Stroke Complicating Thrombolytic Therapy With Tenecteplase for ST Elevation Myocardial Infarction. Two Case Reports. ... The two cases on which we report shed light on the association between fibrinolytic therapy and ischemic stroke, the ... With these observations in mind we report two interesting cases of ischemic stroke which occurred after fibrinolytic therapy ...
Thrombolytic therapy and mortality in patients with acute pulmonary embolism
... thrombolytic therapy was used infrequently. Risk of in-hospital and 30-day mortality appears to be elevated for patients who ... were unlikely candidates for this therapy based on characteristics at presentation, but not for pat … ... received thrombolytic therapy. The overall 30-day mortality rate for patients who received thrombolytic therapy was 17.4% ... Thrombolytic therapy and mortality in patients with acute pulmonary embolism Arch Intern Med. 2008 Nov 10;168(20):2183-90. doi ...
Thrombolytic therapy: MedlinePlus Medical Encyclopedia
Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks ... thrombolytic therapy; Heart attack - thrombolytic therapy; Stroke - thrombolysis; Heart attack - thrombolysis; Myocardial ... Reperfusion therapy; Stroke - thrombolytic; Heart attack - thrombolytic; Acute embolism - thrombolytic; Thrombosis - ... Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks ...
Venous Thromboembolism (VTE) Treatment & Management: Approach Considerations, Anticoagulant Therapy, Thrombolytic Therapy
Thrombolytic Therapy. Thrombolytic therapy dissolves recent clots promptly by activating a plasma proenzyme, plasminogen, to ... Thrombolytic therapy speeds pulmonary tissue reperfusion and rapidly reverses right heart failure. It also improves pulmonary ... Anticoagulant and thrombolytic therapy options are available for the treatment of venous thromboembolism (VTE). Anticoagulant ... Heparin therapy should be discontinued immediately before delivery, and then both heparin and warfarin therapy can be started ...
Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction
The National Institutes of Health (NIH) Consensus Development Program: Thrombolytic Therapy in Thrombosis
... following initiation of thrombolytic therapy, reaching a maximum in approximately six hours. *Thrombolytic therapy helps to ... the normal control value before thrombolytic therapy is started. *Begin the thrombolytic infusion. During therapy there should ... What Are the Economic Aspects Involved in Thrombolytic Therapy? The thrombolytic agents available at present, streptokinase and ... therapy for these disorders. With the advent of thrombolytic therapy, this is no longer true for a large number of cases. ...
Thrombolytic therapy in A&E departments in the U.K. | Emergency Medicine Journal
Thrombolytic therapy - SmartEngage
... thrombolytic therapy; Heart attack - thrombolytic therapy; Stroke - thrombolysis; Heart attack - thrombolysis; Myocardial ... Reperfusion therapy; Stroke - thrombolytic; Heart attack - thrombolytic; Acute embolism - thrombolytic; Thrombosis - ... Thrombolytic therapy. Tissue plasminogen activator; TPA; Alteplase; Reteplase; Tenecteplase; Activase thrombolytic agent; Clot- ... Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks ...
Guidelines for Thrombolytic Therapy for Frostbite - PubMed
The data are insufficient to support standardized treatment of all patients with frostbite with thrombolytic therapy. The ... Use of Intra-arterial Thrombolytic Therapy for Acute Treatment of Frostbite in 62 Patients with Review of Thrombolytic Therapy ... Guidelines for Thrombolytic Therapy for Frostbite Sean Hickey 1 , Amy Whitson 2 , Larry Jones 2 , Lucy Wibbenmeyer 3 , Colleen ... Guidelines for Thrombolytic Therapy for Frostbite Sean Hickey et al. J Burn Care Res. 2020. . ...
The National Institutes of Health (NIH) Consensus Development Program: Thrombolytic Therapy in Thrombosis
... following initiation of thrombolytic therapy, reaching a maximum in approximately six hours. *Thrombolytic therapy helps to ... the normal control value before thrombolytic therapy is started. *Begin the thrombolytic infusion. During therapy there should ... What Are the Economic Aspects Involved in Thrombolytic Therapy? The thrombolytic agents available at present, streptokinase and ... therapy for these disorders. With the advent of thrombolytic therapy, this is no longer true for a large number of cases. ...
Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the german...
Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the german ... Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the german ... Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the german ...
Predictors of in-hospital and long-term clinical outcome in elderly patients with massive pulmonary embolism receiving...
... receiving thrombolytic therapy for pulmonary embolism (PE). DESIGN: Case-control retrospective study. SETTING: General medicine ... receiving thrombolytic therapy for pulmonary embolism (PE). DESIGN: Case-control retrospective study. SETTING: General medicine ... receiving thrombolytic therapy for pulmonary embolism (PE). DESIGN: Case-control retrospective study. SETTING: General medicine ... receiving thrombolytic therapy for pulmonary embolism (PE). DESIGN: Case-control retrospective study. SETTING: General medicine ...
Myocardial Infarction Treatment & Management: Approach Considerations, Prehospital Care, Emergency Department Care
Thrombolytic Therapy. Thrombolytic therapy has been shown to improve survival rates in ST-segment elevation myocardial ... Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and ... Anticoagulation and Thrombolytic Therapy in STEMI. In the previous 2004 guidelines on STEMI management, patients treated with ... 61] Thrombolytic therapy administered within the first 2 hours can occasionally abort myocardial infarction and dramatically ...
Sudden Unilateral Vision Loss in a Patient Who Received Intravenous Thrombolytic Therapy<...
Sudden Unilateral Vision Loss in a Patient Who Received Intravenous Thrombolytic Therapy. Chest. 2021 Dec;160(6):e669-e672. ... Sudden Unilateral Vision Loss in a Patient Who Received Intravenous Thrombolytic Therapy. / Shah, Tejas E.; Vij, Rohin; Kim, Yu ... title = "Sudden Unilateral Vision Loss in a Patient Who Received Intravenous Thrombolytic Therapy", ... Sudden Unilateral Vision Loss in a Patient Who Received Intravenous Thrombolytic Therapy. ...
Should older patients with acute myocardial-infarction receive thrombolytic therapy
Subjects: Thrombolytic Therapy - Digital Collections - National Library of Medicine Search Results
Start Over You searched for: Subjects Thrombolytic Therapy ✖Remove constraint Subjects: Thrombolytic Therapy ... Thrombolytic Therapy. Thrombosis -- drug therapy. Thrombosis -- prevention & control. Venous Thromboembolism -- drug therapy. ... Cerebrovascular Disorders -- drug therapy. Embolism -- drug therapy. Fibrinolytic Agents -- therapeutic use. Medication Therapy ... Thrombolytic Therapy. Venous Thrombosis -- prevention & control. Humans. Indiana. United States 2. Antithrombotics: indications ...
Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction
What are the thrombolytic therapy options for pulmonary embolism (PE)?. What is the efficacy of thrombolytic therapy for ... Why is thrombolytic therapy indicated in patients with coronary atherosclerosis?. What is the mainstay of thrombolytic therapy ... Complications of Thrombolytic Therapy. Prior to thrombolytic therapy, risk assessment is mandatory. Particular safety concerns ... What are limitations of thrombolytic therapy for deep vein thrombosis (DVT)?. What is the role of systemic thrombolytic therapy ...
Repeated Thrombolytic Therapy in Patients with Recurrent Acute Ischemic Stroke
Thrombolytic therapy. The detailed protocol for thrombolytic treatment has been previously reported.16-19 Thrombolytic ... Repeated thrombolytic therapy could be considered, even if patients have had previous history of thrombolytic treatments. ... We explored the number and outcome of patients with repeated thrombolytic therapy in the era of multimodal thrombolytic ... The median time from the onset of symptoms to thrombolytic therapy was 120 hours for the first thrombolytic treatment, and 125 ...
Acute Management of Stroke: Initial Treatment, Thrombolytic Therapy, Stabilization of Airway and Breathing
Thrombolytic Therapy. Current treatments for acute ischemic stroke include IV thrombolytic therapy with tissue-type plasminogen ... most likely to benefit from thrombolytic therapy and the potential benefits of extending the window for thrombolytic therapy ... The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012 May. 43(5):1315-22. [QxMD ... What is the indication for thrombolytic therapy in the acute management of stroke? ...
Preventing Chronic Disease | Emergency Medical Services Capacity for Prehospital Stroke Care in North Carolina - CDC
Not included in basic topics was thrombolytic therapy. One system did not answer the question on thrombolytic therapy, and one ... Not included was thrombolytic therapy.. f Determined by Fisher exact test.. g Validated stroke scales and screens named on the ... notably thrombolytic therapy (1). With proper education and use of protocols, EMS personnel can screen for stroke in the field ... education on thrombolytic therapy, and a policy to notify hospitals in advance. Although we observed positive changes overall, ...
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. part 33 « Diabetes: symptoms, causes, prevention, care...
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. part 33. Thus, ximelagatran therapy is a promising ... Home , Other , The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. part 33 ... We do not yet know whether therapy with aspirin plus clopidogrel is as effective as warfarin therapy, or whether treatment with ... However, recent results with warfarin raise the possibility that ximelagatran therapy may be useful for this indication, either ...
Special Issues - Thrombosis Research - Journal - Elsevier
Other Treatments
Thrombolytic drug therapy involves the use of fibrinolytic agents that break up fibrin, a core component of clots. These ... Thrombolytic Therapy. Some patients who have massive blood clots, or disease that progresses despite anticoagulant treatment, ... that do not involve the use of thrombolytic or clot-dissolving therapies. ... More recently, with some high-risk cases of pulmonary embolism, advanced therapies like mechanical thrombectomy may be used in ...
HTA 101: X. Selected Issues in HTA
Thrombolytic therapy for ischemic stroke. Box X-2 shows examples of health technologies for which good evidence exists of ... and gene therapy substituting for some pharmaceutical or biological therapies (Wilson 2012). Disruptive innovations can present ... Also, therapies that do not yield a statistically significant treatment effect across a study population―and that may be ... Therapies that yield a statistically significant treatment effect across a study population may not necessarily work for all ...
human cardiovascular system (anatomy) | Britannica
Dr. Michael Ginsburg, MD | Pleasant Prairie, WI | Healthgrades
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism - Université de Bretagne...
Impact of Hospital Level on Stroke Outcomes in the Thrombolytic Therapy Era in Northeast Thailand: A Retrospective Study
Refludan®50 mg/vial
lepirudin (rDNA) for injection
Monitoring and Adjusting Therapy; Concomitant Use With Thrombolytic Therapy.) ... Concomitant Use With Thrombolytic Therapy. Clinical trials in HIT patients have provided only limited information on the ... It occurred in patients with acute myocardial infarction who were started on both REFLUDAN and thrombolytic therapy with rt-PA ... There have been reports of intracranial bleeding with REFLUDAN in the absence of concomitant thrombolytic therapy (see ADVERSE ...
IschemicThrombosisStreptokinaseTimes for thrombolytic therapyAngioplastyStrokeAlteplaseAnticoagulationSubmassive pulmonaryEfficacyTherapeuticThrombolysisMyocardial infarctionMortalityAntithromboticBypass graftsPatencyRisk of recurrentAdjunctiveInfusionAnticoagulantHeparinMedicationsOutcomeACCPPatientsProstheticDissolveTissueAgentsVersusBloodWoundVascularAgentMedicinesEchocardiographyReducesHealthcareSystemicGuidelinesSymptomsOutcomesJournalDrugsDrug
Ischemic7
- After numerous case series and smaller prospective studies suggesting benefit for thrombolytic therapy (tPA), the early 90s ushered in the era of thrombolytic RCTs for acute ischemic stroke. (emottawablog.com)
- The date associated with the time that Intra-arterial (IA) thrombolytic therapy was initiated to a patient with ischemic stroke at this hospital. (jointcommission.org)
- Efficacy of telemedicine for thrombolytic therapy in acute ischemic stroke: A meta-analysis. (mayoclinic.org)
- BACKGROUND: The benefit of intravenous thrombolytic therapy for acute ischemic stroke is time dependent. (duke.edu)
- METHODS: We analyzed Medicare beneficiaries aged ≥65 years receiving intravenous thrombolytic treatment for acute ischemic stroke at 1490 Get With The Guidelines-Stroke hospitals during January 2006 and December 2009 (preintervention, n=10 804) and January 2010 and December 2014 (postintervention, n=31 249). (duke.edu)
- CONCLUSIONS: Target: stroke quality initiative was associated with faster thrombolytic treatment times for acute ischemic stroke and modestly lower 1-year all-cause and cardiovascular readmissions. (duke.edu)
- Adjunctive anti-ischemic therapies such as intravenous nitroglycerin or beta blockade can be useful to minimize ischemia. (blogspot.com)
Thrombosis7
- Thrombolytic therapy has been described in several case reports as beneficial in patients with cerebral venous thrombosis (CVT). (medscape.com)
- Anticoagulation and thrombolytic therapy were also given for treatment of a left popliteal artery thrombosis. (hindawi.com)
- Purpose: To develop a porcine carotid artery thrombosis model for the evaluation of thrombolytic therapy and adjunctive angioplasty procedures. (houstonmethodist.org)
- Deep vein thrombosis (DVT) can be treated with medical therapy and/or surgical intervention. (nm.org)
- Thrombolytic Therapy for Prosthetic Valve Thrombosis in Pregnant Women? (jwatch.org)
- Blood thinning agents is usually the first choice of therapy for acute Deep Vein Thrombosis. (myzeo.com)
- CONCLUSION: Prosthetic valve thrombosis was accompanied by sub-optimal anticoagulant therapy. (bvsalud.org)
Streptokinase2
- Streptokinase infusion initially yielded conflicting results until the Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico (GISSI) trial in 1986, which validated streptokinase as an effective therapy and established a fixed protocol for its use in AMI. (medscape.com)
- Streptokinase therapy followed by intravenous heparin infusion was given and the clot lysed successfully. (who.int)
Times for thrombolytic therapy1
- To assist hospitals in providing faster thrombolytic treatment, the American Heart Association launched target: stroke quality initiative in January 2010 which disseminated feasible strategies to shorten door-to-needle times for thrombolytic therapy. (duke.edu)
Angioplasty6
- Further therapy, such as cardiac catheterization with angioplasty and stenting, may be needed. (medlineplus.gov)
- thrombolytic agents, angioplasty and valves. (who.int)
- A large randomised multicentre trial is needed to compare the relative merits of intravenous thrombolytic treatment in a local hospital with primary angioplasty after transfer in selected high risk patients with acute myocardial infarction. (bmj.com)
- Several randomised trials have recently shown that primary coronary angioplasty-defined as angioplasty performed on the infarct related vessel-during the early hours of acute myocardial infarction, without the use of thrombolytic agents, offers certain advantages over intravenous thrombolytic treatment. (bmj.com)
- The time loss and the risks associated with transportation might negate (part of) the benefits of primary angioplasty compared to thrombolytic treatment. (bmj.com)
- To compare intravenous thrombolytic treatment in a local facility with primary coronary angioplasty after transportation to a referral centre for interventional treatment of coronary artery disease, a multicentre randomised trial is currently planned in The Netherlands. (bmj.com)
Stroke12
- Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks and stroke. (medlineplus.gov)
- Thrombolytic medicines are approved for the emergency treatment of stroke and heart attack . (medlineplus.gov)
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). (nih.gov)
- Thrombolytic Therapy: A Stroke of Luck? (emottawablog.com)
- Also in 2001, the ICRH/Heart and Stroke Foundation sponsored the Canadian Consensus Conference on Acute Stroke Imaging of Thrombolytic Therapy. (nih.gov)
- Recent recommendations from the American Heart Association/American Stroke Association and FDA remove or make less specific many previous contraindications and warnings for therapy. (jointcommission.org)
- Our analyses of immune cell subsets suggest that BR therapy substantially decreases neutrophils in blood following a stroke. (nature.com)
- Electrochemiluminescence detection demonstrates that BR therapy reduces cytokine storm in plasma and ELISA demonstrates reduced levels of matrix metalloproteinase-9 (MMP-9) in the plasma and brains at different time points post-stroke. (nature.com)
- Our study is the first to show that BR therapy leads to profoundly improved stroke outcomes in mice and that the improved outcomes are mediated via MMP-9. (nature.com)
- Current treatments for acute stroke include thrombolytic therapy through the administration of tissue plasminogen activator and the surgical removal of the clot. (nature.com)
- These results reveal a possible therapy of using blood for brain protection from a stroke. (nature.com)
- His special interests include thrombolytic therapy, mechanical thrombectomy, stroke, long term management of stroke/rehabilitation, subarachnoid and intracerebral hemorrhage. (neurox.us)
Alteplase1
- Regarding catheter-directed therapy, patients who received low-dose catheter-directed alteplase were also concurrently anticoagulated with systemic unfractionated heparin in the Ultrasound-Assisted, Catheter-Directed Th rombolysis for Acute Intermediate-Risk Pulmonary Embolism (ULTIMA) trial. (ccjm.org)
Anticoagulation4
- [ 27 ] Guidelines have been developed for optimal management of anticoagulation therapy in patients with VTE. (medscape.com)
- In a study of patients with a first VTE who did not have cancer and who received different durations of anticoagulant treatment, the results indicated a similar risk of recurrent VTE whether anticoagulation therapy was stopped after 3 months or a longer period of treatment was provided. (medscape.com)
- Specific therapy for CVT involves anticoagulation or thrombolytic therapy. (medscape.com)
- Existing data support the use of systemic anticoagulation as an initial therapy in all patients, even in the presence of intracranial hemorrhage. (medscape.com)
Submassive pulmonary2
Efficacy2
- The efficacy of thrombolytic therapy was assessed using carotid arteriography and intravascular ultrasound. (houstonmethodist.org)
- Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. (cdc.gov)
Therapeutic1
- Further, addition of MMP-9 in blood diminishes therapeutic effects of the BR therapy. (nature.com)
Thrombolysis2
- Fibrin-bound plasminogen will be converted by thrombolytic drugs to plasmin, the rate-limiting step in thrombolysis. (medscape.com)
- The findings of this overview demonstrate that insufficient clinical outcome data are available to support or to refute the routine use of intravenous heparin therapy after thrombolysis. (ox.ac.uk)
Myocardial infarction2
- Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. (ox.ac.uk)
- Intravenous heparin is routinely given after thrombolytic therapy for patients with acute myocardial infarction in the United States and in some, but by no means all, other countries. (ox.ac.uk)
Mortality1
- 1-4 Rapid and sustained patency of the infarct related vessel is obtained in most patients, resulting in a lower mortality and less reinfarction without exposing them to the bleeding risks associated with thrombolytic treatment. (bmj.com)
Antithrombotic2
- Large randomized studies of heparin (and of new antithrombotic regimens) are needed to establish the role of such therapy. (ox.ac.uk)
- Since publication of the seventh American College of Chest Physicians (ACCP) supplement on antithrombotic and thrombolytic therapy, the results of clinical trials have provided important new information on the management of thromboembolic disorders, and the science of developing recommendations has advan. (bvsalud.org)
Bypass grafts1
- Thrombolytic therapy for thrombosed arterial bypass grafts has received little attention in the medical literature. (jamanetwork.com)
Patency1
- Follow-up showed continued patency nine months following thrombolytic therapy. (jamanetwork.com)
Risk of recurrent1
- The researchers discovered that thrombolytic therapy lowered the risk of recurrent pulmonary embolism by 60 percent compared to anticoagulant therapy. (rxwiki.com)
Adjunctive1
- It provides not only a model for the evaluation of thrombolytic therapy but also a practical training tool for adjunctive endovascular interventions. (houstonmethodist.org)
Infusion2
- These preliminary results suggest that transjugular local infusion of thrombolytic agents can be an effective treatment for symptomatic, thrombosed dural sinuses. (elsevier.com)
- These patients were treated with infusion of a thrombolytic agent into the dural venous sinus, utilizing microcatheter technique. (medscape.com)
Anticoagulant13
- Anticoagulant and thrombolytic therapy options are available for the treatment of venous thromboembolism (VTE). (medscape.com)
- Anticoagulant therapy prevents further clot deposition and allows the patient's natural fibrinolytic mechanisms to lyse the existing clot. (medscape.com)
- A recent review of studies found that thrombolytic therapy (dissolving of blood clots) for pulmonary embolism lowered the risk of death compared to anticoagulant therapy (prevention of blood clots). (rxwiki.com)
- The researchers also found that thrombolytic therapy carried an increased risk for major bleeding in comparison to anticoagulant therapy. (rxwiki.com)
- The review included 16 studies published between 1970 and 2014 that compared thrombolytic therapy to anticoagulant therapy for pulmonary embolism patients. (rxwiki.com)
- Thrombolytic therapy involves using medication to breakup blood clots, whereas anticoagulant therapy involves using medication to reduce the body's ability to make clots in the first place. (rxwiki.com)
- The findings showed that thrombolytic therapy reduced the risk of death by 47 percent compared to anticoagulant therapy. (rxwiki.com)
- The patients who had thrombolytic therapy were 2.73 times more likely to have major bleeding, and 4.63 times more likely to have an intracranial hemorrhage, than those who received anticoagulant therapy. (rxwiki.com)
- The pulmonary embolism patients who were 65 years old and younger only had a 25 percent increased risk of major bleeding with thrombolytic therapy versus anticoagulant therapy. (rxwiki.com)
- When analysis was restricted to the eight studies that included intermediate-risk pulmonary embolism patients, thrombolytic therapy lowered the risk of death by 52 percent and increased the risk of major bleeding events by 3.19 times compared to anticoagulant therapy. (rxwiki.com)
- More research is also needed to see if anticoagulant medication could be used in combination with thrombolytic therapy. (rxwiki.com)
- Two patients responded to heparinization and optimization of anticoagulant therapy. (bvsalud.org)
- According to the guidelines , in patients with VTE (DVT of the leg or PE), direct-acting oral anticoagulants (DOACs), specifically apixaban, dabigatran, edoxaban, or rivaroxaban, are recommended over vitamin K antagonists (VKAs) as treatment-phase (first 3 months) anticoagulant therapy. (medscape.com)
Heparin4
- Heparin therapy should be discontinued immediately before delivery, and then both heparin and warfarin therapy can be started post partum. (medscape.com)
- Heparin is the first line of therapy. (medscape.com)
- We performed a systematic overview of the 6 randomized controlled trials (1,735 patients) to summarize the available data concerning the risks and benefits of intravenous heparin versus no heparin after thrombolytic therapy. (ox.ac.uk)
- Similar rates of recurrent ischemia and reinfarction were observed among those allocated to heparin therapy or control. (ox.ac.uk)
Medications1
- Also, the studies used various types and doses of thrombolytic medications, and the researchers did not have data on patient characteristics such as demographics or medical history. (rxwiki.com)
Outcome1
- however, as the NINDS investigators concluded, the earlier that IV thrombolytic therapy is initiated, the better the patient outcome. (jointcommission.org)
ACCP1
- Regardless, Dr. Katyal is correct in highlighting that the new 2016 ACCP guidelines now give a grade of 2B for thrombolytic therapy in the treatment of massive pulmonary embolism. (ccjm.org)
Patients8
- At our institution, the current practice is to target an anti-Xa level of 0.3 to 0.7 μg/mL in patients receiving catheter-directed therapy for large-volume pulmonary embolism. (ccjm.org)
- Les dossiers de 622 patients âgés en moyenne de 58,3 ans (écart type 12,9) ont été étudiés. (who.int)
- Des stratégies préventives doivent être mises en œuvre afin d'améliorer le pronostic à long terme des patients libyens et de réduire la morbidité et la mortalité globales dues à la coronaropathie. (who.int)
- Identify appropriate pulmonary embolism patients for catheter-based therapy. (chestnet.org)
- Describe need for thrombolytic therapy in patients with intermediate risk PE. (chestnet.org)
- Eleven patients received thrombolytic therapy and nine of them responded to it. (bvsalud.org)
- Most patients responded to medical therapy alone. (bvsalud.org)
- In most patients with acute PE that is not associated with hypotension, the guidelines recommend against systemically administered thrombolytic therapy. (medscape.com)
Prosthetic2
Dissolve3
- The history of thrombolytic therapy began in 1933, when it was discovered that filtrates of broth cultures of certain streptococcal strains (beta-hemolytic streptococci) could dissolve a fibrin clot. (medscape.com)
- Thrombolytic therapy is a treatment in which you are given medicines through a drip to dissolve a blood clot that is narrowing or blocking a coronary artery. (wa.gov.au)
- In certain situations, a thrombolytic medication may be used to dissolve the blood clot. (nm.org)
Tissue1
- The most commonly used drug for thrombolytic therapy is tissue plasminogen activator (tPA), but other drugs can do the same thing. (medlineplus.gov)
Agents1
- The thrombolytic agents available today are serine proteases that work by converting plasminogen to the natural fibrinolytic agent plasmin. (medscape.com)
Versus1
- Versus, electrophysiologic study indicated that initial thrombolytic therapy in acute ingestions. (aaan.org)
Blood3
- The development of novel cell tracking methodologies for cell localization represent part of the Strategic Plan for Cell-based Therapies for Heart, Lung, Blood and Sleep Disorders developed by the Working Group on Cell-based Therapies in May 2002. (nih.gov)
- Further, we have demonstrated that the addition of MMP-9 to the blood diminishes the protective effect of the BR therapy. (nature.com)
- The traditional treatment of subarachnoid hemorrhage (SAH) from a ruptured cerebral aneurysm included strict blood pressure control, with fluid restriction and antihypertensive therapy. (medscape.com)
Wound1
- Thrombolytic therapy */ @213 WOUND 1. (cdc.gov)
Vascular1
- Thrombolytic therapy should play an increasing role in vascular surgery. (jamanetwork.com)
Agent1
- t-PA has increasingly been used as the first-choice thrombolytic agent. (medscape.com)
Medicines1
- Ideally, you should receive thrombolytic medicines within the first 30 minutes after arriving at the hospital for treatment. (medlineplus.gov)
Echocardiography1
- Echocardiography provides rapid, noninvasive assessment of cardiac structure and function, detects intracardiac thrombi when present, and assists in formulating appropriate therapy and prognosis. (vin.com)
Reduces1
- Following the treatment, we demonstrate that the BR therapy significantly reduces the cytokine storm in the plasma. (nature.com)
Healthcare1
- Information about a therapy, service, product or treatment does not imply endorsement and is not intended to replace advice from your healthcare professional. (wa.gov.au)
Systemic1
- This selective lysis avoids thrombolytic effects that could aggravate or produce systemic hemorrhagic complications. (elsevier.com)
Guidelines1
- Results Current guidelines and reviews propose different criteria and recommendations for SVT treatment, whereupon an increasing stringency in the therapy recommendations in recent years can be observed. (thieme-connect.de)
Symptoms1
- The Ozonated Oils are amazing skin care products widely used for effective therapy of acne, eczema and psoriasis symptoms, wounds, burns of different origin, as well as some other skin imperfections such as cellulite and wrinkles. (ozonefactory.net)
Outcomes2
- Outcomes are better if you receive a thrombolytic drug within 12 hours after the heart attack starts. (medlineplus.gov)
- Improving Outcomes in Liver Transplantation From Donation After Circulatory Death: The Role of Thrombolytic Therapy. (ochsner.org)
Journal1
- Journal of Endovascular Therapy , 7 (3), 227-235. (houstonmethodist.org)
Drugs2
- What are thrombolytic drugs? (clevelandclinic.org)
- Many providers outside the United States choose this because it's cheaper than other thrombolytic drugs. (clevelandclinic.org)
Drug1
- Accordingly, it is necessary to use measures for rational use of drug therapy 1 . (bvsalud.org)